433,545 Shares in Elevation Oncology, Inc. (NASDAQ:ELEV) Bought by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new position in Elevation Oncology, Inc. (NASDAQ:ELEV) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 433,545 shares of the company’s stock, valued at approximately $260,000. GSA Capital Partners LLP owned about 0.73% of Elevation Oncology at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of ELEV. SG Americas Securities LLC purchased a new position in Elevation Oncology during the third quarter worth $28,000. XTX Topco Ltd bought a new stake in shares of Elevation Oncology in the second quarter valued at about $103,000. American Century Companies Inc. raised its holdings in shares of Elevation Oncology by 55.7% in the second quarter. American Century Companies Inc. now owns 49,222 shares of the company’s stock valued at $133,000 after acquiring an additional 17,602 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Elevation Oncology during the second quarter valued at approximately $175,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Elevation Oncology in the 2nd quarter worth $415,000. Institutional investors own 83.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ELEV. Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Elevation Oncology in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Elevation Oncology in a report on Wednesday, August 7th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Elevation Oncology currently has an average rating of “Buy” and a consensus price target of $7.80.

Elevation Oncology Stock Performance

NASDAQ ELEV opened at $0.60 on Friday. The company has a current ratio of 17.77, a quick ratio of 17.77 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $35.67 million, a price-to-earnings ratio of -0.74 and a beta of 1.24. The stock has a 50-day moving average of $0.58 and a 200 day moving average of $1.74. Elevation Oncology, Inc. has a twelve month low of $0.44 and a twelve month high of $5.83.

Elevation Oncology (NASDAQ:ELEV) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.02). Sell-side analysts anticipate that Elevation Oncology, Inc. will post -0.84 EPS for the current fiscal year.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.